DK3141548T3 - Fremgangsmåder og mellemprodukter til fremstilling af azaindoler - Google Patents

Fremgangsmåder og mellemprodukter til fremstilling af azaindoler Download PDF

Info

Publication number
DK3141548T3
DK3141548T3 DK16190960.1T DK16190960T DK3141548T3 DK 3141548 T3 DK3141548 T3 DK 3141548T3 DK 16190960 T DK16190960 T DK 16190960T DK 3141548 T3 DK3141548 T3 DK 3141548T3
Authority
DK
Denmark
Prior art keywords
azaindoles
intermediates
preparation
methods
Prior art date
Application number
DK16190960.1T
Other languages
English (en)
Inventor
Gerald J Tanoury
Young Chun Jung
Derek Magdziak
Adam Looker
Billie J Kline
Olmo Beatriz Dominguez
Václav Jurcík
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK3141548T3 publication Critical patent/DK3141548T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
DK16190960.1T 2011-07-05 2012-07-03 Fremgangsmåder og mellemprodukter til fremstilling af azaindoler DK3141548T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504351P 2011-07-05 2011-07-05
US201261636296P 2012-04-20 2012-04-20
EP12735411.6A EP2729465A2 (en) 2011-07-05 2012-07-03 Processes and intermediates for producing azaindoles

Publications (1)

Publication Number Publication Date
DK3141548T3 true DK3141548T3 (da) 2020-07-06

Family

ID=46513874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16190960.1T DK3141548T3 (da) 2011-07-05 2012-07-03 Fremgangsmåder og mellemprodukter til fremstilling af azaindoler

Country Status (19)

Country Link
US (5) US8513414B2 (da)
EP (2) EP2729465A2 (da)
JP (3) JP2014520815A (da)
KR (1) KR20140058547A (da)
CN (2) CN106432311A (da)
AR (1) AR087069A1 (da)
AU (1) AU2012279046B2 (da)
BR (1) BR112014000115A2 (da)
CA (1) CA2839937C (da)
DK (1) DK3141548T3 (da)
ES (1) ES2804528T3 (da)
MX (1) MX2013015147A (da)
NZ (2) NZ714502A (da)
PL (1) PL3141548T3 (da)
PT (1) PT3141548T (da)
RU (1) RU2014103806A (da)
TW (1) TW201321378A (da)
WO (1) WO2013006634A2 (da)
ZA (1) ZA201400049B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676285A (zh) * 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
RS55341B1 (sr) 2009-06-17 2017-03-31 Vertex Pharma Inhibitori replikacije virusa gripa
RU2014103806A (ru) 2011-07-05 2015-08-10 Вертекс Фармасьютикалз Инкорпорейтед Способы и промежуточные соединения для получения азаиндолов
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
KR20160045070A (ko) 2013-08-22 2016-04-26 버텍스 파마슈티칼스 인코포레이티드 동위원소 풍부 아자인돌
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
DK3421468T3 (da) * 2013-11-13 2021-01-11 Vertex Pharma Fremgangsmåder til fremstilling af inhibitorer af re-plikation af influenzavira
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
KR20180088466A (ko) * 2015-12-09 2018-08-03 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제 저해제, 활용 방법 및 그 용도
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
BR112019004091B1 (pt) 2016-09-09 2023-02-14 F. Hoffmann-La Roche Ag Processo para a preparação de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3', 4'-d]pirrol
PL3558321T3 (pl) 2016-12-23 2023-10-23 Felicitex Therapeutics, Inc. Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
CN113121452A (zh) * 2021-05-10 2021-07-16 甘肃堡昌化工有限公司 一种硫酸法尿嘧啶的精制工艺
CN113851244A (zh) * 2021-09-18 2021-12-28 浙江爱索拓科技有限公司 一种含放射性同位素碳-14废水的处理方法
CN113896716A (zh) * 2021-10-27 2022-01-07 浙江爱索拓科技有限公司 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
EP1675830A4 (en) * 2003-09-30 2008-08-20 Scios Inc HETEROCYCLIC AMIDES AND SULFONAMIDES
JP4605606B2 (ja) 2004-01-30 2011-01-05 長瀬産業株式会社 軸不斉を有する光学活性な4級アンモニウム塩およびそれを用いたα−アミノ酸およびその誘導体の製造方法
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
CN101676285A (zh) 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US8921376B2 (en) 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
NZ575274A (en) * 2006-08-08 2010-11-26 Chugai Pharmaceutical Co Ltd Pyrimidine derivative as pi3k inhibitor and use thereof
MX2009006345A (es) 2006-12-14 2009-06-23 Vertex Pharma Compuestos utiles como inhibidores de proteina cinasa.
BRPI0819223A2 (pt) * 2007-11-05 2020-08-18 Novartis Ag derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
EP2247592B1 (en) * 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
RS55341B1 (sr) 2009-06-17 2017-03-31 Vertex Pharma Inhibitori replikacije virusa gripa
RU2014103806A (ru) 2011-07-05 2015-08-10 Вертекс Фармасьютикалз Инкорпорейтед Способы и промежуточные соединения для получения азаиндолов
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP2014532765A (ja) 2011-11-07 2014-12-08 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 炎症性疾患を処置する方法およびそのために有用な薬学的組み合わせ物
KR20160045070A (ko) 2013-08-22 2016-04-26 버텍스 파마슈티칼스 인코포레이티드 동위원소 풍부 아자인돌

Also Published As

Publication number Publication date
US8796453B2 (en) 2014-08-05
US8946425B2 (en) 2015-02-03
US20150099884A1 (en) 2015-04-09
US20130303764A1 (en) 2013-11-14
BR112014000115A2 (pt) 2016-10-04
NZ714502A (en) 2017-04-28
ES2804528T3 (es) 2021-02-08
KR20140058547A (ko) 2014-05-14
EP3141548B1 (en) 2020-04-08
JP2017002067A (ja) 2017-01-05
JP6761448B2 (ja) 2020-09-23
TW201321378A (zh) 2013-06-01
WO2013006634A3 (en) 2013-05-10
JP2014520815A (ja) 2014-08-25
CA2839937A1 (en) 2013-01-10
JP2018162314A (ja) 2018-10-18
NZ619699A (en) 2016-03-31
US20140309421A1 (en) 2014-10-16
EP2729465A2 (en) 2014-05-14
US8513414B2 (en) 2013-08-20
AU2012279046A1 (en) 2014-01-23
EP3141548A1 (en) 2017-03-15
MX2013015147A (es) 2014-03-27
AR087069A1 (es) 2014-02-12
ZA201400049B (en) 2015-04-29
WO2013006634A2 (en) 2013-01-10
CA2839937C (en) 2020-11-03
RU2014103806A (ru) 2015-08-10
CN103702998A (zh) 2014-04-02
US9090614B2 (en) 2015-07-28
PL3141548T3 (pl) 2020-09-07
US20150284388A1 (en) 2015-10-08
EP3141548B9 (en) 2020-08-12
WO2013006634A9 (en) 2013-03-21
AU2012279046B2 (en) 2017-08-31
PT3141548T (pt) 2020-07-10
US20130102782A1 (en) 2013-04-25
CN106432311A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2768524T3 (da) PD-L1-baseret immunterapi
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
DK3556774T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK2718404T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY4115Q (es) Reloj
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
HK1213521A1 (zh) 多肽的應用
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK2771022T3 (da) Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK3299356T3 (da) Fremgangsmåde til fremstilling af pleuromutiliner
BR112013025299A2 (pt) conjunto de ancoragem
ITTO20110705A1 (it) Procedimento di preparazione della moxifloxacina cloridrato e relativi intermedi
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
DK2581003T3 (da) Apparat til tilberedning af fødevarer